Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2025

Conditions
Breast CancerRecurrent Breast CancerStereotactic Body RadiotherapyEstrogen Receptor Positive TumorHer2-negative TumorSurgery
Interventions
PROCEDURE

Surgical resection

Surgical resection for their metastatic lesions will be performed. Achievement of tumor-free margin is not mandatory.

RADIATION

Stereotactic body radiotherapy

Deliver appropriate metastasis directed radiotherapy while minimizing exposure of surrounding normal tissues. Total radiation dose and fractions are various according to metastatic lesions (57\~97.5Gy/6\~10 Fraction).

PROCEDURE

Radiofrequency ablation

RFA is a localized thermal treatment technique designed to induce tumor destruction by heating the tumor tissue to temperatures that exceed 60℃. The alternating current of radiofrequency waves passing down from an uninsulated electrode tip into the surrounding tissues generates changes in the direction of ions and creates ionic agitation and frictional heating. This tissue heating then drives extracellular and intracellular water out of the tissue, resulting in tissue destruction by coagulative necrosis.

Trial Locations (1)

135720

RECRUITING

Gangnam Severance Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Severance Hospital

OTHER

collaborator

Samsung Medical Center

OTHER

collaborator

Asan Medical Center

OTHER

lead

Gangnam Severance Hospital

OTHER

NCT03750396 - Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer | Biotech Hunter | Biotech Hunter